Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results

BİRİNCİ, Hakkı; SÜLLÜ, Yüksel; NİYAZ, LEYLA; Eski Yucel, Ozlem

Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results

Leyla NİYAZ, (Yrd. Doç. Dr., Ondokuz Mayis University, Ophthalmology, Samsun -Türkiye)

Yüksel SÜLLÜ, (Prof. Dr., Ondokuz Mayis University, Ophthalmology, Samsun - Türkiye)

Hakkı BİRİNCİ, (Prof. Dr., Ondokuz Mayis University, Ophthalmology, Samsun - Türkiye)

Özlem EŞKİ YÜCEL (Yrd. Doç. Dr., Ondokuz Mayis University, Ophthalmology, Samsun -Türkiye)

Retina-Vitreus

1 0

Yıl: 2017 Cilt: 26 Sayı: 4 Sayfa Aralığı: 312 - 317 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results

Öz:

Amaç: Santral retinal ven tıkanıklığı (SRVT) ve retinal ven dal tıkanıklığına (RVDT) bağlı maküla ödemi (MÖ) olan gözlerde intravitreal ranibizumab (İR) ve deksametazon implantın (İDİ) etkinliğini değerlendirmek ve karşılaştırmak. Gereç ve Yöntemler: Bu çalışma retrospektif olarak yapıldı. SRVT veya RVDT'ye bağlı MÖ tedavisi için 0.5mg/0.05mL İR veya 0.7mg İDİ yapılan hastalar çalışmaya dahil edildi. En iyi düzeltilmiş görme keskinliği (EİDGK) ve santral maküla kalınlığındaki (SMK) başlangıca göre değişim etkinlik kriterleri olarak kabul edildi. Bulgular: Kırk üç (24 RVDT, 19 SRVT) hasta çalışmaya dahil edildi. Tüm gruplarda EİDGK ve SMK başlangıca göre düzeldi. RVDT hastalarında, İR grubunda ortalama EİDGK artışı 4., 5. ve 6. aylarda istatistiksel olarak daha fazlayken, İDİ grubunda ortalama SMK azalması 1. ayda istatiksel olarak daha fazlaydı. SRVT hastalarında, EİDGK ve SMK'daki düzelme açısından İR ve İDİ grupları arasında istatistiksel olarak anlamlı fark yoktu. Altı ayda, ortalama enjeksiyon sayıları, İR ile tedavi edilen RVDT ve SRVT hastalarında 2.3 ve 2.7 , İDİ ile tedavi edilen RVDT ve SRVT hastalarında 1.4 ve 1.3 'tü. İDİ ile tedavi edilen SRVT hastalarının 1 (%11.1)'inde, RVDT hastalarının 3 (%33.3)'ünde göz içi basınç (GİB) artışı görüldü. Sonuç: SRVT ve RVDT'ye bağlı maküla ödemli gözlerde İR ve İDİ görme keskinliği artışı ve anatomik düzelme sağlamaktadır. RVDT hastalarında İR'nin daha fazla EDGK artışı sağladığı görülmüştür. İDİ ile tedavi edilen hastalarda GİB artışı görülebilir

Anahtar Kelime:

Konular: Göz Hastalıkları

Retinal Ven Tıkanıklığına Bağlı Maküler Ödem Tedavisinde İntravitreal Ranibizumab ve Dexamethasone İmplant: Altı Aylık Sonuçlar

Öz:

Objective: To assess and compare the effi cacy of intravitreal ranibizumab (IR) and dexamethasone implant (IDI) in eyes with macular edema (ME) secondary to branch and central retinal vein occlusion (BRVO and CRVO). Material and Methods: This is a retrospective study. Patients who had received IR 0.5mg/0.05mL or IDI 0.7mg for the treatment of ME due to BRVO or CRVO were included in the study. Effi cacy outcomes were considered as the change from baseline in best-corrected visual acuity (BCVA) and central macular thickness (CMT). Results: Forty three patients were included (24 BRVO, 19 CRVO) in the study. BCVA and CMT improved from baseline in all groups. In BRVO patients, increase of mean BCVA was signifi cantly higher with IR in the 4th, 5th and 6th months, and decrease of mean CMT was signifi cantly higher with IDI only in the 1st month. In CRVO patients, there were not signifi cant differences in BCVA and CMT improvements compared to IR or IDI. The mean number of injections was 2.3 and 2.7 for BRVO and CRVO cases treated with IR, 1.4 and 1.3 for BRVO and CRVO cases treated with IDI in 6 months. Intraocular pressure (IOP) increase occurred in 3(33.3%) BRVO and 1(11.1%) CRVO patients treated with IDI. Conclusion: Intravitreal ranibizumab and IDI provide signifi cant benefi ts in visual acuity gain and anatomic improvement in eyes with ME secondary to BRVO and CRVO. Ranibizumab seems to be more effective in BCVA gain in BRVO patients. Increase in IOP can be observed in IDI treated patients

Anahtar Kelime:

Konular: Göz Hastalıkları

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Bibliyografik

1. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997;115(4):486-91.
2. Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol. 2011;56:281-299.
3. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol. 1984;98:271-82.
4. The Central Vein Occlusion Study Group. Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion. Ophthalmology. 1995;102:1425-33.
5. Pielen A, Feltgen N, Isserstedt C, et al. Effi cacy and safety of intravitreal therapy in macular edema due to branch and central retinal vein occlusion: a systematic review. PLoS One. 2013;8(10):e78538.
6. Ford JA, Clar C, Lois N, et al. Treatments for macular oedema following central retinal vein occlusion: systematic review. BMJ Open. 2014;4(2):e004120.
7. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1102-12.
8. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117(6):1124-33.
9. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal afl ibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015;122(3):538-44.
10. Boyer D, Heier J, Brown DM, et al. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024-32.
11. Scott IU, Ip MS, VanVeldhuisen PC, et al.; SCORE Study Research Group. A randomized trial comparing the effi cacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009;127(9):1115-28.
12. Ip MS, Scott IU, VanVeldhuisen PC, et al.; SCORE Study Research Group. A randomized trial comparing the effi cacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol. 2009;127(9):1101-14.
13. Felinski EA, Antonetti DA. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res. 2005;30(11):949-57.
14. Nauck M, Karakiulakis G, Perruchoud AP, et al. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341(2-3):309-15.
15. Haller JA, Bandello F, Belfort R Jr, et al. OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology. 2010;117(6):1134-1146.
16. Joshi L, Yaganti S, Gemenetzi M, et al. Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol. 2013;97(8):1040-4.
17. Querques L, Querques G, Lattanzio R, et al. Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion. Ophthalmologica. 2013;229(1):21-5.
18. Meyer LM, Schönfeld CL. Secondary glaucoma after intravitreal dexamethasone 0.7 mg implant in patients with retinal vein occlusion: a one-year follow-up. J Ocul Pharmacol Ther. 2013;29(6):560-5.
19. Rabena MD, Pieramici DJ, Castellarin AA, et al. Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina. 2007;27(4):419-25.
20. Priglinger SG, Wolf AH, Kreutzer TC, et al. Intravitreal bevacizumab injections for treatment of central retinal vein occlusion: six-month results of a prospective trial. Retina. 2007;27(8):1004- 12.
21. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008;92(4):518-22.
22. Kinge B, Stordahl PB, Forsaa V, et al. Effi cacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol. 2010;150(3):310-14.
23. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefi ts from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011;118(8):1594-602.
24. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefi ts from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology. 2011;118(10):2041-9.
25. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012;119(4):802-9.
26. Yumusak E, Buyuktortop N, Ornek K. Early results of dexamethasone implant, ranibizumab, and triamcinolone in macular edema due to branchretinal vein occlusion. Eur J Ophthalmol. 2016;26(1):54-9.
27. Hoerauf H, Feltgen N, Weiss C, et al.; COMRADE-C Study Group. Clinical Effi cacy and Safety of Ranibizumab Versus Dexamethasone for Central Retinal Vein Occlusion (COMRADE C): A European Label Study. Am J Ophthalmol. 2016 May 7. pii: S0002- 9394(16)30195-7. doi: 10.1016/j.ajo.2016.04.020. [Epub ahead of print]

APA	NİYAZ L, SÜLLÜ Y, BİRİNCİ H, Eski Yucel O (2017). Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results. , 312 - 317.
Chicago	NİYAZ LEYLA,SÜLLÜ Yüksel,BİRİNCİ Hakkı,Eski Yucel Ozlem Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results. (2017): 312 - 317.
MLA	NİYAZ LEYLA,SÜLLÜ Yüksel,BİRİNCİ Hakkı,Eski Yucel Ozlem Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results. , 2017, ss.312 - 317.
AMA	NİYAZ L,SÜLLÜ Y,BİRİNCİ H,Eski Yucel O Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results. . 2017; 312 - 317.
Vancouver	NİYAZ L,SÜLLÜ Y,BİRİNCİ H,Eski Yucel O Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results. . 2017; 312 - 317.
IEEE	NİYAZ L,SÜLLÜ Y,BİRİNCİ H,Eski Yucel O "Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results." , ss.312 - 317, 2017.
ISNAD	NİYAZ, LEYLA vd. "Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results". (2017), 312-317.

APA	NİYAZ L, SÜLLÜ Y, BİRİNCİ H, Eski Yucel O (2017). Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results. Retina-Vitreus, 26(4), 312 - 317.
Chicago	NİYAZ LEYLA,SÜLLÜ Yüksel,BİRİNCİ Hakkı,Eski Yucel Ozlem Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results. Retina-Vitreus 26, no.4 (2017): 312 - 317.
MLA	NİYAZ LEYLA,SÜLLÜ Yüksel,BİRİNCİ Hakkı,Eski Yucel Ozlem Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results. Retina-Vitreus, vol.26, no.4, 2017, ss.312 - 317.
AMA	NİYAZ L,SÜLLÜ Y,BİRİNCİ H,Eski Yucel O Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results. Retina-Vitreus. 2017; 26(4): 312 - 317.
Vancouver	NİYAZ L,SÜLLÜ Y,BİRİNCİ H,Eski Yucel O Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results. Retina-Vitreus. 2017; 26(4): 312 - 317.
IEEE	NİYAZ L,SÜLLÜ Y,BİRİNCİ H,Eski Yucel O "Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results." Retina-Vitreus, 26, ss.312 - 317, 2017.
ISNAD	NİYAZ, LEYLA vd. "Intravitreal Ranibizumab and Dexamethasone Implant in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion: Six-month Results". Retina-Vitreus 26/4 (2017), 312-317.